What Lab Confirmation Does After a Non-Negative Screen
A non-negative result on an instant cup, dip card, or oral fluid device is not a positive drug test. It is a presumptive screen that must go to a laboratory for confirmatory testing before anyone treats it as positive. Confirmation uses a different, more specific analytical method than the screen, and it identifies and quantifies the exact substance present rather than just flagging a class of drugs.
For buyers building or maintaining a defensible testing program, understanding this two-step structure matters as much as the devices themselves. Below is how initial screening and laboratory confirmation actually work, what the regulations require, and where the Medical Review Officer fits in for DOT-regulated testing.
Why an instant screen is only presumptive
Point-of-collection immunoassay devices, whether a multi-panel cup, a dip card, or an oral fluid swab, work by detecting whether a drug or drug metabolite is present above a set cutoff concentration. Immunoassay antibodies bind to a target class of compounds, but related molecules can sometimes trigger a similar reaction. That cross-reactivity is exactly why a non-negative screen is called presumptive, not positive: the device has told you that something in that drug class appears to be present, not precisely what it is or how much.
This is also why federal drug testing rules build a mandatory second step into the process. Under 49 CFR 40.85, when an initial laboratory test result is at or above the cutoff concentration, the laboratory "must conduct a confirmation test." A result is only reported as confirmed positive after that second test also comes back at or above its own cutoff (49 CFR 40.85).
What confirmatory testing actually does
Confirmation is not a repeat of the screen. Federal regulation defines a confirmatory drug test as "a second analytical procedure performed on a different aliquot of the original specimen to identify and quantify a specific drug or drug metabolite" (49 CFR 40.3). Three things in that definition matter for buyers:
- A different specimen aliquot. The confirmation is run on a fresh portion of the same original sample, not the same material already tested by the screen.
- A different analytical procedure. Laboratories pair chromatography, which physically separates the compounds in a specimen, with mass spectrometry, which identifies each separated compound by its molecular signature. Gas chromatography/mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the chromatography-mass spectrometry techniques laboratories use for this step, and they work on a fundamentally different principle than an antibody-based immunoassay screen.
- Identification and quantification. The confirmatory result names the specific substance and reports a concentration, rather than simply flagging a drug class the way a screen does.
Because the confirmation method targets a specific molecule rather than a class of similar compounds, it resolves the cross-reactivity risk that makes a screen presumptive in the first place. A non-negative screen that was actually triggered by a legal medication or an unrelated compound will typically not confirm, and the specimen is reported negative.
Screening versus confirmation, side by side
| Factor | Initial screen (immunoassay) | Confirmatory test (GC-MS / LC-MS/MS) |
|---|---|---|
| Purpose | Rule out negatives quickly, flag specimens that need further review | Identify and quantify the specific drug or metabolite |
| Method | Antibody-based immunoassay | Chromatography paired with mass spectrometry |
| Specimen used | Initial portion tested | A different aliquot of the same original specimen |
| Cross-reactivity risk | Possible, by design of antibody testing | Not a factor; method targets the specific molecule |
| Result terminology | Non-negative or presumptive positive | Confirmed positive or negative |
| Where it happens | On site, at collection | Certified laboratory |
The MRO review step for DOT testing
For DOT-regulated testing, a laboratory-confirmed positive result does not go straight to the employer. It first goes to a Medical Review Officer, a licensed physician responsible for receiving and reviewing laboratory results and evaluating medical explanations for certain outcomes (49 CFR 40.3). Under 49 CFR 40.123, the MRO must "determine whether there is a legitimate medical explanation for confirmed positive, adulterated, substituted, and invalid results from the laboratory" before that result is reported as verified (49 CFR 40.123).
Only after MRO verification does a DOT-regulated employer have a result it can act on. Part 40 sets the testing and review procedures; the consequence of a verified positive for a driver, including removal from safety-sensitive duty, comes from the agency-specific rule. For motor carriers, 49 CFR 382.215 states that "no driver shall report for duty, remain on duty or perform a safety-sensitive function" after testing positive for controlled substances, and bars an employer with knowledge of that result from permitting the driver to continue (49 CFR 382.215).
Why this structure protects buyers
A program built on screen-then-confirm is more defensible in three ways that matter to HR and safety managers, clinics, and treatment centers:
- It filters false alarms before they become disputes. A non-negative screen that does not confirm never becomes a reportable positive, which limits unnecessary conflict with employees or clients.
- It stands up to challenge. A result identified and quantified by chromatography-mass spectrometry, on a documented chain of custody, is harder to dispute than a screen result alone.
- It keeps roles separated. The collector, the laboratory, and, for DOT testing, the MRO each have a distinct function. No single step decides an outcome by itself.
For volume buyers, this also shapes purchasing. High-quality initial-screen devices reduce the number of non-negatives that need to be sent out, which controls confirmation costs, but the confirmation step itself should never be skipped or treated as optional for any result that will be used in a personnel or compliance decision.
Where lab confirmation supplies fit into a program
Programs that run their own reference or confirmation testing, rather than sending every non-negative to an outside lab, need reagents, calibrators, and controls built for that workflow. ASC stocks drug test kits for laboratories alongside broader laboratory and reference lab drug testing supplies for teams that need to support confirmation-adjacent workflows. For the initial-screen side of the same program, our rapid drug test and screening kits and DOT drug and alcohol testing supplies for transportation companies are built around the same screen-then-confirm structure described above.
For more on what happens to a confirmed result once it reaches a physician reviewer, see our guide to the Medical Review Officer drug test process. For the numbers that separate a negative from a non-negative in the first place, see drug test cutoff levels.
Frequently asked questions
Is a non-negative screen the same as a positive drug test?
No. A non-negative screen is presumptive. Under 49 CFR 40.85, a laboratory must run a confirmatory test on any initial result at or above the cutoff, and only a confirmed result, and for DOT testing an MRO-verified result, is reported as positive.
Why can't the confirmation test just repeat the same screening method?
Because federal regulation defines confirmatory testing as a second analytical procedure on a different specimen aliquot that identifies and quantifies the specific drug or metabolite, not a repeat of the initial method. Repeating the same immunoassay would not resolve the cross-reactivity that made the screen presumptive.
What methods do laboratories use to confirm a non-negative result?
Laboratories pair chromatography, which separates the compounds in a specimen, with mass spectrometry, which identifies each compound by its molecular signature. Gas chromatography/mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) are the chromatography-mass spectrometry techniques used for this step.
Does every non-negative screen get sent for confirmation?
For any result used in a personnel, compliance, or DOT decision, yes. Confirmation should never be skipped for a result that will be acted on, since an unconfirmed screen is presumptive by definition.
Who reviews a confirmed positive result in DOT testing?
A Medical Review Officer, a licensed physician, reviews the laboratory-confirmed result and determines whether there is a legitimate medical explanation before it is reported as verified, per 49 CFR 40.123.
What happens to a driver after a confirmed positive under DOT rules?
Under 49 CFR 382.215, a driver may not perform a safety-sensitive function after testing positive for controlled substances, and an employer with knowledge of that result may not permit the driver to continue in that role.
This article is for general informational purposes and does not constitute legal advice. Screening devices provide presumptive results only; they do not diagnose drug use or guarantee a result. Non-negative screens require laboratory confirmation, and DOT-regulated results require MRO review, before any result is treated as final. Employers should consult qualified legal counsel and their MRO for program-specific guidance.
